Medical student at John Sealy School of Medicine, University of Texas in Galveston

Alleviating Pediatric Fracture Risk Concerns With Asthma ICS, With Lynchi Nguyen

 treated with inhaled corticosteroids (ICS) for asthma did not face a higher risk of fractures—in fact, those managed with short-acting beta agonists (SABA) alone had an 18% higher fracture risk compared with children receiving ICS therapy, according to new data analyzing more than 210,000 pediatric patients.

Asthma remains the most common chronic allergic and respiratory condition in children, and ICS is foundational to long-term asthma control. However, patient and family concerns about the potential skeletal effects of corticosteroids, particularly extrapolated from data on systemic steroids, continue to influence prescribing patterns and parental acceptance.

Lynchi Nguyen, a medical student at John Sealy School of Medicine, University of Texas Medical Branch in Galveston, addressed this concern at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, where she presented data from a large retrospective cohort study aiming to clarify ICS and fracture risk using the TriNetX U.S. Collaborative Network. The analysis included more than 210,000 children aged 6–18 years with asthma. Patients were categorized into 3 mutually exclusive groups: SABA-only therapy, ICS-only therapy, and ICS combined with a long-acting beta agonist (ICS + LABA). To ensure accurate comparisons, cohorts were propensity score matched for age, sex, and comorbidities, with exclusions for obesity, cystic fibrosis, autoimmune disease, and metabolic bone disorders.

The primary outcome was first-time pediatric-specific fracture occurring at least 1 year after medication initiation, including Salter-Harris fractures, torus fractures, greenstick fractures, and bent bone fractures, which are injuries particularly relevant to growing children.

Nguyen and colleagues found that compared with SABA-only controls, children in the ICS-only group demonstrated a lower fracture risk, with a relative risk (RR) of 1.18 (95% CI, 1.11–1.26) for the SABA-only cohort, indicating an 18% higher fracture risk among children treated with SABA alone. In contrast, there was no statistically significant difference in fracture risk between ICS + LABA therapy and SABA-only therapy (RR, 1.05; 95% CI, 0.95–1.15), nor between ICS + LABA and ICS-only regimens (RR, 0.97; 95% CI, 0.86–1.09).

Importantly, ICS use, whether alone or in combination, was not associated with increased fracture risk. In fact, the data suggest that children managed without ICS may face modestly higher fracture risk, potentially reflecting poorer asthma control or greater systemic steroid exposure from exacerbations.

These results reinforce international guideline recommendations that encourage early incorporation of ICS and move away from SABA monotherapy. Nguyen emphasized that inhaled corticosteroids are not equivalent to systemic steroids in their skeletal effects, and these findings should help clinicians confidently counsel families, address misconceptions, and support evidence-based asthma management in children.

“ICS use is not equivalent to systemic steroid use, [it doesn’t] confer the same risks, and that it's safe for our children to be on these medications…[It’s important for clinicians to incorporate] this into their counseling with parents so they don't feel as hesitant to adhere to these asthma regimens that include ICs,” Nguyen said.

Nguyen L, Lee A, Carmichael K, Acevado JA. Fracture Risk Among Pediatric Asthma Patients Treated With Inhaled Corticosteroids: A Retrospective Cohort Study. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Poster #L04

Videos

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Matthew Krantz, MD, from Vanderbilt University Medical Center

HLA-A*32:01 Carrier Screening Feasibility Before Lamotrigine, With Matthew Krantz, MD

New data linked HLA-A*32:01 carriage to lamotrigine-induced drug reaction with 

eosinophilia and systemic symptoms (DRESS)

2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphi

a, Matthew Krantz, MD, from Vanderbilt University Medical Center, addressed how these data should guide management decisions and whether pre-prescription screening is feasible. He said a team led by Elizabeth Phillips, MD, from Vanderbilt, had developed a rapid single allele assay for 32:01 that uses allele-specific primers.

“You don’t get full HLA typing, but you get a binary result of whether an individual is a carrier for a 3201 or not,” Krantz said. “You also don't get information if an individual has 2 copies of a 3201; you would only get…that binary result. It's not a clinically available test, but in research settings where it's been optimized, these tests can be done with a several-hour turnaround. We do think that if these tests were to have evidence of meeting that threshold of a low number needed to test to prevent 1 case, that this is something that could be translated into the clinic.”

In the recently published multi-institutional cohort, HLA-A*32:01 was present in 40% of lamotrigine-induced DRESS cases compared with 5.5% of matched lamotrigine-tolerant controls, corresponding to an odds ratio of 12.1 (95% CI, 4.9–29.8; Bonferroni-corrected 

 < .001). Although this represents a substantial genetic association, DRESS remains rare. Among individuals exposed to high-risk medications for the requisite 2- to 8-week latency period, approximately 1 in 1000 may develop DRESS. At the population level, incidence is estimated at 1 to 3 per 100,000.

Given this low absolute risk, routine pre-prescription high-resolution HLA typing is not currently standard practice. Krantz noted that most patients will not have existing HLA class I data available to guide lamotrigine prescribing. An exception may include patients undergoing bone marrow or solid organ transplantation, where comprehensive HLA typing is already performed.

In situations where HLA-A*32:01 carriage is known, and lamotrigine is strongly indicated, Krantz suggested a risk-mitigation strategy rather than automatic exclusion. Lamotrigine is associated with a spectrum of cutaneous reactions, ranging from mild maculopapular eruptions to severe hypersensitivity. Standard prescribing protocols already emphasize low starting doses with gradual titration to reduce rash risk. In carriers, clinicians could consider even more cautious dose escalation, closer clinical follow-up, and vigilant monitoring for early systemic symptoms such as a rash.

The original cohort included 30 prospectively identified lamotrigine-induced DRESS cases (87% female; 93% self-identified White; median age 33 years [interquartile range, 25–56]) and 300 matched tolerant controls. Krantz acknowledged that the predominantly White, European ancestry composition limits the ability to detect ancestry-specific risk alleles.

“This really requires collaborative networks of academic medical centers identifying and precision phenotyping these individuals, obtaining… genetic data for sequencing, especially for HLA, to be able to generalize these results,” Krantz said. “We're really the first multi-institutional group to kind of show this. The next step would be for replication at other sites.”

Relevant disclosures for Krantz include Silk Road Medical, Inc., Boston Scientific Corporation, and Tactile Systems Technology Inc.

Krantz M, Gangula R, Yu A, et al. HLA-A*32:01 carriage is associated with lamotrigine-induced drug reaction with eosinophilia and systemic symptoms in a US cohort. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2025.12.953

Krantz M. HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD. HCPLive. Published on February 28, 2026. Accessed on February 28, 2026. 

https://www.hcplive.com/view/hla-a-32-01-linked-lamotrigine-dress-risk-matthew-krantz-md

HLA-A*32:01 carrier screening may identify patients at elevated risk for lamotrigine-induced eosinophilia and systemic symptoms, Krantz says at AAAAI 2026.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An exploratory pooled analysis of the Phase 3 METREX, METREO, and MATINEE trials has demonstrated that mepolizumab (Nucala; GSK) consistently reduced the annualized rate of moderate or severe exacerbations in people with 

 (COPD) compared with placebo, regardless of blood eosinophil count (BEC) variability pattern.

Mepolizumab was approved by the United States (US) Food and Drug Administration (FDA) in May 2025 as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype.

 BECs are an established biomarker of type 2 inflammation in COPD and are associated with increased exacerbation risk. Yet BEC levels are dynamic, influenced by infections, corticosteroid exposure, circadian variation, and other factors. Real-world data suggest that only 5–18% of patients demonstrate persistently high BEC ≥300 cells/µL, while nearly 30% exhibit intermittent elevations. This variability complicates clinical decision-making and raises important questions about how to identify patients most likely to benefit from biologic therapy.

The analysis, presented by Gerald Criner, MD, Chair and Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University, at the 

 2026 Annual Meeting held in Philadelphia, Pennsylvania, valuated mepolizumab 100 mg subcutaneously versus placebo in patients ≥40 years of age with COPD receiving inhaled triple therapy. Patients were stratified by longitudinal pre-randomization BEC patterns to assess whether variability in eosinophil levels influences response.

Criner and colleaguges found that across patients with evidence of type 2 inflammation, mepolizumab consistently reduced the annualized rate of moderate or severe exacerbations compared with placebo, regardless of BEC variability pattern.

In Subgroup 1 (BEC ≥300 cells/µL at screening and baseline), exacerbation rates were reduced from 1.31 events/year with placebo to 0.95 with mepolizumab (rate ratio [RR], 0.73; 95% CI 0.61–0.88), corresponding to a 27% relative risk reduction.

Subgroup 2 (persistently ≥300 cells/µL across all pre-randomization timepoints) showed a numerical reduction from 1.11 to 0.97 events/year (RR, 0.88; 95% CI 0.70–1.11), equating to a 12% relative risk reduction.

Subgroup 3, (high type 2 inflammation at screening [≥300 cells/µL] but short-term variability [<300 cells/µL at baseline]), experienced a decrease from 1.27 to 0.99 events/year (RR, 0.78; 95% CI 0.60–1.01), representing a 22% relative risk reduction.

Notably, Subgroup 4 (≥300 cells/µL at any pre-randomization timepoint with at least one measurement <150 cells/µL) demonstrated one of the largest treatment effects. Exacerbation rates declined from 1.43 to 0.91 events/year (RR, 0.64; 95% CI 0.45–0.89), corresponding to a 36% relative risk reduction. This subgroup also had among the highest placebo exacerbation rates, suggesting that patients with marked BEC variability may represent a particularly high-risk and responsive phenotype.

Patients meeting the US-approved eosinophilic phenotype definition (Subgroup 5: ≥150 cells/µL at screening and/or ≥300 cells/µL in the prior year) experienced a reduction from 1.36 to 1.10 events/year (RR, 0.81; 95% CI 0.72–0.91), a 19% relative risk reduction. Similar significant reductions were observed in Subgroup 6 (RR, 0.83; 17% risk reduction) and Subgroup 7 (RR, 0.79; 21% risk reduction).

In contrast, Subgroup 8 of non-type 2 COPD (persistently <150 cells/µL) showed no meaningful benefit; rates increased from 1.17 to 1.47 events/year (RR, 1.26; 95% CI 0.98–1.61), indicating no protective effect in the absence of type 2 inflammation.

For exacerbations requiring emergency department (ED) visit and/or hospitalization, results generally mirrored the moderate/severe findings, with efficacy across BEC levels except in Subgroup 8 in those without type 2 COPD Again, no meaningful benefit was observed (RR, 1.11; 95% CI 0.63–1.97).

Subgroup 3 demonstrated the largest relative reduction in severe outcomes, with rates decreasing from 0.27 to 0.12 events/year (RR, 0.44; 95% CI 0.25–0.80), representing a 56% relative risk reduction.

Subgroup 5 showed a reduction from 0.26 to 0.20 events/year (RR, 0.77; 95% CI 0.60–0.99), corresponding to a 23% relative risk reduction. Subgroups 6 and 7 demonstrated consistent directional improvements (RR, 0.77 and 0.76, reflecting 23% and 24% relative risk reductions, respectively).

Overall, this analysis supports the use of mepolizumab in patients with inadequately controlled COPD and documented type 2 inflammatory activity, consistent with its US-approved indication, and suggests that requiring persistent eosinophilia may unnecessarily exclude patients who could achieve meaningful risk reduction.

“Mepolizumab consistently reduces exacerbation rates in a wide spectrum of patients with COPD and type 2 inflammation versus placebo, both in those who have high and low variability in their BECsover time, as well as those with historically elevated BEC, prior to therapy initiation. These results support the use of mepolizumab in patients who have shown signsof type 2 inflammation, without necessarily being persistently eosinophilic,” Criner and colleagues wrote in their poster.

1. Criner GJ, Watz H, Han MK, et al. MepolizumabImproves Exacerbation Outcomes in Patients with COPD with Type 2 Inflammation and Variable Eosinophil Patterns. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Poster #L01.

2. Johnson V. FDA Approves Mepolizumab for Eosinophilic COPD. Article. HCPLive. May 22, 2025. 

https://www.hcplive.com/view/fda-approves-mepolizumab-for-eosinophilic-copd

Articles

Exploratory pooling of phase 3 METREX, METREO, and MATINEE evaluated mepolizumab 100 mg SC added to inhaled triple therapy in COPD patients ≥40 with type 2 inflammation. Despite substantial longitudinal blood eosinophil count (BEC) variability, mepolizumab reduced annualized moderate/severe exacerbations versus placebo across multiple BEC-pattern strata, including intermittent and highly variable eosinophilia. Largest effect occurred in those with any BEC ≥300 and at least one <150. No benefit was observed in persistently low BEC (<150) non–type 2 COPD. Severe ED/hospitalization events similarly declined in most type 2 strata.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Mepolizumab Reduces Type 2 COPD Exacerbations Across Variable BEC Levels

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

New data presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia from February 27 – March 2, strengthen evidence that HLA-A*32:01 carriage is strongly associated with lamotrigine-induced drug reaction with 

 in a US cohort. In an interview conducted at AAAAI, Matthew Krantz, MD, from Vanderbilt University Medical Center, discussed the clinical implications of the findings.

“This is really kind of a discovery HLA association given that HLA testing of class 1 and 2 alleles isn't done on a routine basis for all patients and integrated into their electronic health record,” Krantz said. “This kind of test may be most helpful at this point for helping assess causality for patients who experience stress where they're receiving multiple medications at the same time.”

Krantz explained that DRESS presents a particular diagnostic challenge because of its delayed onset. Symptoms typically emerge 2 to 8 weeks after a medication is started, a window during which patients are often exposed to multiple new therapies. This latency makes it difficult to confidently identify the true culprit drug and complicates decisions about which agents can be safely restarted.

“We want to precisely have them avoid medications that put them at risk of recurrent reactions,” he continued.

Investigators recognized antibiotics, allopurinol, and anti-seizure drugs are the main culprits of DRESS. The team sought to see whether HLA-A*32:01 could serve as a genetic predictor of lamotrigine-induced DRESS.

Krantz and colleagues conducted a prospectively identified, multi-institutional case-control study including patients from Vanderbilt University Medical Center (VUMC) and Mass General Brigham. The cohort comprised 30 lamotrigine-induced DRESS cases (RegiSCAR ≥4) and 300 matched lamotrigine-tolerant controls drawn from VUMC’s BioVU biobank, matched 10:1 by age, sex, and self-identified race.

The cases were predominantly female (87%) and largely self-identified White (93%), with a median age of 33 years (interquartile range, 25–56). High-resolution HLA class I typing was performed using Illumina MiSeq, supplemented by HLA imputation from genotyping array data (SNP2HLA). Association testing was conducted at the locus, haplotype, and amino acid levels using midasHLA and R software, with Bonferroni correction applied.

At the locus level, HLA-A*32:01 was strongly associated with lamotrigine-induced DRESS (odds ratio [OR], 12.1; 95% CI, 4.9–29.8; Pc < .001). Carriage rates were 40% among cases versus 5.5% among tolerant controls. No haplotypes met Bonferroni-corrected significance.

From a genetic epidemiology standpoint, an OR of approximately 12 represents a substantial effect size. As Krantz noted in the interview, most common-disease genetic associations yield ORs between 1 and 2. The magnitude of association here supports biologic plausibility and positions HLA-A*32:01 as a meaningful risk marker.

At the amino acid level, the investigators identified 2 significant HLA-A positions associated with DRESS: lysine at position 109 (OR, 2.4; 95% CI, 1.5–3.3; Pc < .001) and serine at position 77 (OR, 1.9; 95% CI, 1.0–2.7; Pc < .001). These findings suggest that structural features of the HLA-A molecule may contribute to altered peptide presentation and T-cell activation in lamotrigine hypersensitivity.

Despite the strength of the association, Krantz emphasized that translation into routine pre-prescription screening requires careful consideration of predictive value.

“At this point, what inhibits the ability to really implement HLA testing in the clinic is that while it may have a decent negative predictive value, meaning that if you do not carry the risk allele you're much less likely to develop the disease, it doesn't completely exclude it,” Krantz said, “That’s some work that needs to continue to be done before this can really be translated into the clinic where clinicians are using it for pre-prescription testing.”

. 2026;157(2):AB428. doi:https://doi.org/10.1016/j.jaci.2025.12.953

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Gerald Appel, MD, is a professor of clinical medicine, director of clinical nephrology, and director of the Glomerular Disease Center at Columbia University.

Luis Sanchez Russo, MD, is a nephrologist affiliating with Advent Health.

Associate Professor, Drexel University, Co-Director Autoimmune Kidney Disease Center, Allegheny Health Network

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era

On Rare Disease Day 2026, 4 clinicians share their insights and perspectives on the groundbreaking improvements in the rapidly evolving field of rare kidney diseases.

Despite persistent awareness gaps in rare kidney disease care, a wave of FDA approvals and phase 3 trial successes in 

 alongside updated 2025 KDIGO Practice Guidelines, has fueled growing clinician optimism about a rapidly advancing, disease-modifying treatment era.

Rare kidney diseases remain complex and underrecognized, leaving both patients and clinicians with challenges in early diagnosis, risk stratification, and long-term management. Yet recent scientific advances and regulatory approvals are beginning to reshape the therapeutic landscape.

Momentum in rare kidney disease care has accelerated with multiple FDA approvals supported by pivotal clinical trial data. In IgAN, 

demonstrated significant reductions in proteinuria and preservation of kidney function in the NefIgArd trial, while 

, a dual endothelin-angiotensin receptor antagonist, showed positive outcomes in the PROTECT study. The addition of 

, an endothelin A receptor antagonist, further underscores the diversification of therapeutic strategies in IgAN, with the ALIGN Phase III trial demonstrating clinically meaningful reductions in proteinuria, a key surrogate for slowing disease progression. Iptacopan, a factor B inhibitor targeting the alternative complement pathway, reported encouraging efficacy in the APPLAUSE-IgAN trial, highlighting a precision-based approach to treatment.

In C3G, iptacopan also showed promising results in the 

, alongside other complement-targeted therapies such as 

 and danicopan, reflecting growing opportunities for disease modification in a previously limited treatment space.

These advances are complemented by the updated 

, which provide evidence-based recommendations to support clinicians in diagnosis, monitoring, and treatment selection, fostering a more standardized and patient-centered approach.

Together, these therapies, spanning endothelin-angiotensin signaling modulation, complement inhibition, and targeted anti-inflammatory strategies, illustrate a shift toward precision medicine in rare kidney disease. 

6 New Kidney Disease Medications Approved in 2025. National Kidney Foundation. Published January 21, 2026. 

https://www.kidney.org/news-stories/6-new-kidney-disease-medications-approved-2025

Sayna Norouzi, MD, Cheung K, Skolnik E, Peleg Y. 2025 KDIGO Guideline Update for IgAN. Hcplive.com. Published January 14, 2026. Accessed February 28, 2026. https://www.hcplive.com/view/2025-kdigo-guideline-update-for-igan

Perkovic V, Barratt J, Rovin BH, et al; APPLAUSE‑IgAN Investigators. 

Alternative complement pathway inhibition with iptacopan in IgA nephropathy.

 N Engl J Med. 2025;392(6):531‑543. doi:10.1056/NEJMoa2410316. Published online 2024 Oct 25.

Kavanagh D, Bomback AS, Vivarelli M, et al. 

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomized, double‑blind, placebo‑controlled, phase 3 study.

 Lancet. 2025;406(10512):1587‑1598. doi:10.1016/S0140‑6736(25)01148‑1.

Lafayette R, et al; NefIgArd Investigators. 

Efficacy and safety of a targeted‑release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2‑year results from a randomized phase 3 trial.

KDIGO IgAN and IgA Vasculitis Work Group; Rovin BH, Barratt J, Cook HT, et al. 

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

 Kidney Int. 2025;108(4S):S1‑S71. doi:10.1016/j.kint.2025.04.004.

Novartis receives FDA accelerated approval for Fabhalta (iptacopan), the first and only complement inhibitor for reduction of proteinuria in adults with primary IgA nephropathy.

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful proteinuria reduction in patients with IgA nephropathy (ALIGN).

On Rare Disease Day 2026, clinicians share their perspective on the evolving landscape for IgAN and C3G. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

GLP-1s Linked to Reduced Asthma Exacerbations, With Ruchi Patel, MD

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy. 

What CAFETERIA Means for Long-Term OIT Goals, with Scott Sicherer, MD

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

FDA News

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

What to Expect for Sleep Improvement With Tapinarof in AD, With Druhan Howell, MD

UChicago GI faculty bring expert endoscopy and IBD care closer to you, with seamless hospital follow-up and cutting-edge clinical trials.

Expanding Access, Advancing Science- How the University of Chicago Is Redefining IBD Care Across Chicagoland

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Mohammad Anadani, MD, is the chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center.

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Latest News

Alleviating Pediatric Fracture Risk Concerns With Asthma ICS, With Lynchi Nguyen

HLA-A*32:01 Carrier Screening Feasibility Before Lamotrigine, With Matthew Krantz, MD

Mepolizumab Reduces Type 2 COPD Exacerbations Across Variable BEC Levels

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

Rare Disease Day 2026: Kidney Diseases Enter Optimistic Therapeutic Era